Despite "another impressive quarterly revenue beat" on Tuesday and solid guidance, Vertex stock dipped on light profit.

VERX stock could present an entry point as it pulls back to its 10-week moving average. Not to be confused with Vertex Pharmaceuticals, Vertex is a company specializing in consulting services and ...

Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...

Vertex has built an empire in cystic fibrosis (CF) treatment, recently crowning its dominance with Alyftrek's approval last month. This latest CF drug adds even more firepower to a franchise ...

In Vertex's most recent quarter, the company grew revenue at an 18% y/y pace to $170.4 million. This isn't bad: but we note that several points of Vertex's growth are stemming from recent ...